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ABSTRACT
Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with 
BRAFV600E–mutated melanoma. However, primary and secondary resistances restrict 
long-lasting therapy success. Combination therapies are therefore urgently needed. 
Here, we evaluate the cellular effect of combining a MEK inhibitor with a genotoxic 
apoptosis inducer. Strikingly, we observed that an activated MAPK pathway promotes 
in several melanoma cell lines the pro-apoptotic response to genotoxic stress, 
and MEK inhibition reduces intrinsic apoptosis. This goes along with MEK inhibitor 
induced increased RAS and P-AKT levels. The protective effect of the MEK inhibitor 
depends on PI3K signaling, which prevents the induction of pro-apoptotic PUMA 
that mediates apoptosis after DNA damage. We could show that the MEK inhibitor 
dependent feedback loop is enabled by several factors, including EGF receptor and 
members of the SPRED family. The simultaneous knockdown of SPRED1 and SPRED2 
mimicked the effects of MEK inhibitor such as PUMA repression and protection from 
apoptosis. Our data demonstrate that MEK inhibition of BRAFV600E-positive melanoma 
cells can protect from genotoxic stress, thereby achieving the opposite of the intended 
anti-tumorigenic effect of the combination of MEK inhibitor with inducers of intrinsic 
apoptosis. 
INTRODUCTION
Melanoma constitutes a very heterogenous cancer 
type which stands out by its high plasticity. However, 
a common feature of most melanomas is the activation 
of the MAPK pathway, which is found in more than 
80% of melanomas. In many cases, this is attributed to 
the expression of oncogenic BRAF which is located 
directly upstream of MEK. Consequently, the MAPK 
pathway emerged as a promising therapeutic target. In 
patients carrying the oncogenic BRAF variant BRAFV600E, 
treatment with the second generation BRAF inhibitors 
vemurafenib (PLX4032) and dabrafenib (GSK2118436) 
have led to significant improvement of progression-
free and overall survival and thus constitute the most 
successful treatment strategies since decades [1-3]. 
Highly increased target protein specificity as well as a 
strong potency to inhibit MAPK signaling are responsible 
for this success [4]. However, despite the striking results 
that were achieved, emerging inhibitor resistance leads to 
high relapse rates. Secondary reactivation of the MAPK 
pathway is a commonly observed resistance phenomenon 
which is mediated by acquired mutations in ERK1/2 
upstream components such as NRAS, MEK or BRAF 
itself [5-7] or by overexpression of MEK effectors such as 
COT and several receptor tyrosine kinases [5, 8-10]. Direct 
inhibition of MEK circumvents this problem, as it directly 
prevents ERK1/2 activation, and thus the application 
of MEK1/2 inhibitors such as selumetinib (AZD6244) 
and trametinib (GSK1120212) is pursued for melanoma 
treatment as well [11, 12]. Indeed, patients preselected for 
the BRAFV600E mutation showed an improved response 
to selumetinib or trametinib when compared to standard 
chemotherapy [11, 12]. The combination of BRAF and 
MEK inhibitors constitutes an additional clinical strategy 
and leads to a better progression free survival than BRAF 
inhibitor monotherapy. Still, the development of resistant 
tumors as well as a significant group of non-responders 
remains a pressing problem [13]. It is generally believed 
that the strong activation of the MAPK pathway which 
is observed in most melanomas mediates a strong anti-
apoptotic response and limits the efficiency of DNA 
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damaging agents [14]. As a consequence, combinations of 
MAPK pathway inhibitors and chemotherapeutic agents or 
other pathway inhibitors arise as rationale and are already 
tested in clinical trials (http://clinicaltrials.gov). 
Here we describe the effect of the combination 
of a MEK inhibitor and, representative for a genotoxic 
apoptosis inducer, the DNA damaging agent cisplatin in 
a panel of melanoma cell lines. Unexpectedly, we found 
that MEK inhibition leads to the protection from cisplatin-
induced apoptosis in some cell lines. This was caused by 
a MEK-inhibitor induced activation of the PI3K/AKT 
pathway, resulting in transcriptional repression of the pro-
apoptotic gene BBC3, encoding PUMA. Mechanistically, 
MEK inhibition relieved several negative feedback loops 
which include SPRY and SPRED proteins and resulted in 
enhanced RAS signaling. Receptor tyrosine kinases were 
involved in this mechanism. 
Our data demonstrate for the first time that MAPK 
pathway inhibition of BRAFV600E-mutated melanoma can 
not only lack an efficient pro-apoptotic effect, but even 
allows a better survival in presence of a classical inducer 
of intrinsic apoptosis. As a consequence, MAPK pathway 
inhibition can even worsen the outcome of melanoma 
treatment under certain conditions. 
RESULTS
MEK inhibition can protect melanoma cells from 
genotoxic apoptosis
Most melanoma cell lines are susceptible to 
inhibition of BRAF or MEK. Accordingly, MEK 
Figure 1: MEK inhibition can protect from cisplatin-induced apoptosis. A: Surviving cells after cisplatin treatment in presence 
of DMSO or PD. An equal number of cells was seeded, and cells were treated with cisplatin (10 µM), PD (2 µM) or DMSO as indicated for 
48h. The number of living cells was determined at the end of the experiment, and the graph depicts the percentage of cell number compared 
to the DMSO treated control in absence of cisplatin. Data were derived from two experiments each performed in triplicates. B: as A, but 
data are presented in % of seeded cells in order to evaluate the reduction of the original cell number. C: FACS profile of A375, LOX IMVI 
and 451Lu cells cultivated with cisplatin (10 µM) in presence of DMSO or PD (2 µM) for 48h. D: Percent change of sub-G1 fraction of 
cells co-treated for 48h with PD (2 µM) and cisplatin (10 µM), compared to cisplatin alone. Data are derived from two experiments each 
performed in triplicates. E: Indicated cell lines were treated with cisplatin (10 µM) and PD (2 µM) or DMSO for 48 hours. Cell lysates 
were blotted and levels of P-FOXO1/3a (Thr24/32), P-AKT (Ser473), P-ERK1/2 (Thr202/Tyr204), cleaved caspase 3, and β-actin were 
determined.
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inhibition led to apoptosis and growth reduction in 
all cell lines from our melanoma cell panel (Figure 
S1A-C). However, intrinsic or acquired resistance is a 
major problem in the clinic, thus providing a reason to 
combine MEK inhibitors with other anticancer drugs such 
as chemotherapeutic agents. We therefore investigated 
whether the anti-tumorigenic effect of MEK inhibition 
could be enhanced by combination with an apoptosis 
inducer. Chemotherapeutic agents including platinum 
compounds are applied in combination therapies in 
clinical trials for cutaneous and uveal melanomas (www.
clinicaltrials.gov). As cisplatin is a well-described 
DNA damaging compound which activates the intrinsic 
apoptosis pathway, we used it as representative genotoxic 
apoptosis inducer. We tested the effect of combining the 
non-competitive MEK inhibitor PD184352 (in short: PD) 
with cisplatin in five BRAFV600E-mutated melanoma cell 
lines. PD inhibits MAPK activity with IC50 values ranging 
from 100 to 500 nM [15], and we chose a concentration 
of 2 µM of the inhibitor to efficiently block MAPK 
signaling (Figure S1A). In all cell lines, cisplatin alone 
led to a strong reduction of cell number after two days 
of treatment compared to the DMSO control which was 
allowed to grow in absence of cisplatin (Figure 1A, gray 
bars). However, three cell lines showed unexpectedly an 
enhanced cell number when they were treated with PD in 
addition to cisplatin (Figure 1A, white bars). To estimate 
the degree of cisplatin induced cell death, we related 
the counted cell numbers to the number of seeded cells 
before treatment (Figure 1B). A decreased rate of cisplatin 
induced cell death was responsible for the relative increase 
in cell number in the PD treated melanoma cells A375, 
Figure 2: Activated AKT pathway mediates the protective effect of MEK inhibition. A: A375, LOX IMVI, RPMI 7951 
and 451Lu cells were treated with PD (2 µM) and LY294002 (10 µM) as indicated for 24 hours. Cell lysates were blotted and analyzed 
for presence of P-AKT (Ser473), P-ERK1/2 (Thr202/Tyr204), and β-actin. B: A375 and LOX IMVI cells were treated with PD (2 µM) 
for 24 hours. Active RAS was precipitated from whole cell lysates, and RAS levels were determined. Lysates treated with GDP or GTP 
served as negative and positive control, respectively. Input lysates were blotted and analyzed for presence of β-actin. C: Cells were treated 
as described in B, and lysates were analyzed by western blot. Levels of P-AKT (Ser473), P-CRAF (Ser259), P-MEK1/2 (Ser217/221) 
and P-ERK1/2 (Thr202/Tyr204) were determined. β-actin served as loading control. D: A375 and LOX IMVI cells were infected with 
myrAKT3 or vector control and were treated with cisplatin (10 µM) for 2 days. Cell lysates were blotted and analyzed for presence of 
P-AKT (Ser473), P-ERK1/2 (Thr202/Tyr204), cleaved caspase 3 and β-actin. E: Cells and supernatant of myrAKT3 or vector control 
expressing cells were collected after 2 days of cisplatin (10 µM) treatment, DNA content was stained using propidium iodide and cell cycle 
profiles were determined. The figure shows the relative rate of cell death. The proportion of cells in sub-G1 of empty vector-transfected 
cells served as control and were set as 100%. 
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LOX IMVI and RPMI 7951 (Figure 1C-E). All three cell 
lines show only weak apoptosis induction by PD alone 
(Figure S1C). In Mel Ho and 451Lu cells, which display 
high apoptosis induction by PD alone (Figure S1C), the 
combination of PD and cisplatin had an additive inhibitory 
effect (Figure 1B-D). 
As cisplatin is a known inducer of the MAPK 
pathway [16], thus possibly affecting the efficacy of PD, 
we determined the extent of ERK1/2 activation after PD 
treatment in absence or presence of cisplatin. An efficient 
inhibition of ERK1/2 phosphorylation was detected under 
all conditions (Figure 1E). Interestingly, the PD-mediated 
apoptosis-protective effect observed in A375, LOX IMVI, 
and RPMI 7951 cells went along with a solid increase in 
P-AKT levels in both absence and presence of cisplatin, 
indicating AKT activation (Figure 1E). Activation of 
AKT was furthermore supported by the observation that 
phosphorylation of the transcription factors FOXO1/3a 
were enhanced at the AKT-dependent positions Thr24 
and Thr32. None of these effects were detected in 
the cell lines 451Lu and Mel Ho which are highly 
sensitive to MEK inhibitor (Figure S3). Importantly, the 
structurally unrelated MEK inhibitor U0126 had a similar 
effect as PD184352 on cisplatin sensitivity and AKT 
phosphorylation, as exemplified for A375 cells (Figure 
S2A, B).
MEK inhibition by PD can activate AKT in a 
PI3K dependent manner
To check whether Ser473 phosphorylation after 
MEK inhibition is a consequence of PI3K activation, we 
applied the PI3K inhibitor LY294002 in addition to PD. 
Elevated P-AKT Ser473 levels could be prevented by 
additional administration of the PI3K inhibitor in A375, 
LOX IMVI and RPMI 7951 cells (Figure 2A). In 451Lu 
cells, the low P-AKT levels did not change after either 
PD or LY294002 treatment. These data indicate that MEK 
inhibitor induced AKT activation is mediated in a PI3K 
dependent manner. To determine if PI3K activation goes 
along with increased activity of its upstream activator 
RAS, we performed a RAS GTPase assay (Figure 2B). 
While active, GTP-bound RAS was virtually undetectable 
in DMSO-treated A375 and LOX IMVI cells, MEK 
inhibition led to robust RAS activation. The extent of this 
activation correlated with the levels of activated AKT and 
Figure 3: PUMA contributes to cisplatin induced apoptosis and is negatively regulated by PD-induced AKT. A: A375 
and LOX IMVI cells were treated with PD (2 µM) or the solvent DMSO for 24h in absence or presence of cisplatin (10 µM). Levels of 
BBC3 mRNA were determined by real-time PCR. Error bars: SD of three independent experiments, each done in triplicate. B: As A, but 
PUMA protein levels were determined by western blot analysis. β-actin served as loading control. C: Determination of PUMA protein 
levels in A375 and LOX IMVI transfected with a control vector or the myrAKT3 overexpression vector. Where indicated, cells were treated 
with cisplatin (10 µM) for 24h. β-actin served as loading control. D: A375 and LOX IMVI cells were treated with BBC3 siRNA. 24h after 
transfection, cells were treated with cisplatin (10 µM) for 24h. Knockdown was confirmed by real-time analysis (left) and protein blot 
(right), as described above. E: Western blot showing the induction of P-p53 (Ser15) and cleaved caspase 3 in control and BBC3 knockdown 
cells in absence or presence of cisplatin (10 µM, 24h). 
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CRAF, which are induced downstream of RAS (Figure 
2C). In addition, MEK1/2 phosphorylation at positions 
Ser117/221 was elevated (Figure 2C). It is important to 
note that PD184352 prevents MEK1/2 activation, but still 
allows phosphorylation at Ser117/221 [6, 17], which might 
thus accumulate when upstream signaling is enhanced.
The PI3K/AKT pathway mediates the protective 
effect of MEK inhibitor treatment.
To address whether the observed AKT activation 
could be the reason for conveying the anti-apoptotic effect, 
we overexpressed constitutively active myristoylated 
AKT3 (myrAKT3) in melanoma cell lines. Activated AKT 
could be visualized by an increase in P-AKT (Ser473) 
levels (Figure 2D). P-ERK1/2 levels were not affected. In 
presence of cisplatin, apoptosis was reduced in myrAKT3-
expressing cells, as demonstrated by reduced levels of 
cleaved caspase 3 (Figure 2D) and a strong decrease of 
the sub-G1 fraction compared to control cells (Figure 2E). 
Altogether, similar to MEK inhibition, overexpression of 
myrAKT3 enhanced the resistance to genotoxic stress. 
Conversely, pharmacological inhibition of PI3K by GDC-
0941 enhanced the inhibitory effect of cisplatin both 
in absence and in presence of MEK inhibitor (Figure 
S4B). In absence of cisplatin, GDC-0941 also inhibited 
cell growth in both cell lines, and this effect was further 
enhanced by PD in A375 cells (Figure S4A). 
Figure 4: EGFR signaling is implicated in MEK inhibitor induced AKT activation. A: Inhibition of EGFR abrogates PD 
induced AKT phosphorylation. Upper image: Western blot showing expression of EGFR in A375 and LOX IMVI cells. Lower image: 
Protein blot of A375 and LOX IMVI cells treated for 24h with DMSO, PD (2 µM), AG1478 (20 µM) or both inhibitors in combination. 
Levels of P-ERK1/2 (Thr202/Tyr204) and P-AKT (Ser473) were determined. β-actin served as reference. B: Quantification of cisplatin-
treated A375 and LOX IMVI cells in presence of MEK- and EGFR inhibitors. 1x105 cells were seeded and treated with PD (2 µM), 
AG1478 (10 µM), or a combination of both in presence of cisplatin (10 µM). The number of surviving cells was determined 48h later. Data 
are presented as % of seeded cells and are derived from two experiments each performed in triplicates. C (upper image): Effect of EGF 
stimulation on the c-RAF/ERK1/2 and PI3K pathways in 451Lu and MeWo cells. Cells were stimulated with EGF for 15 minutes, and 
levels of EGFR, P-CRAF (Ser259), P-AKT (Ser473) and P-ERK1/2(Thr202/Tyr204) were determined by western blot analysis. β-actin 
served as loading control. C (lower image): Effect of EGF stimulation on sensitivity of 451Lu and MeWo cells towards cisplatin in presence 
of PD. 1x105 cells were seeded and treated with DMSO, PD (2 µM), or PD (2 µM) in combination with 8 nM EGF in presence of cisplatin 
(10 µM). The number of surviving cells was determined 48h later. Data are presented as % of seeded cells and are derived from triplicates. 
D: Western blot showing the effect of PD treatment (2 µM) on P-AKT and P-ERK1/2 in control and EGF-treated 451Lu and MeWo cells. 
Cell lysates were blotted and analyzed for presence of P-AKT (Ser473), P-ERK1/2 (Thr202/Tyr204), and β-actin.
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Reduction of PUMA mediates the protective effect 
of PD towards cisplatin
To find out how MEK inhibition influences 
genotoxic apoptosis, we screened a human apoptosis 
primer library and found a strong cisplatin-mediated 
induction of BBC3 (encoding PUMA), which was 
reduced by PD (Figure 3A, B) as well as U0126 (Figure 
S2C). The BBC3 gene product PUMA is a BH3-only, 
pro-apoptotic member of the BCL2 family. PUMA is 
involved in the induction of apoptosis after DNA damage 
[18] and PUMA levels are strongly reduced in human 
melanomas, indicating the importance of a tight control 
of PUMA levels during melanomagenesis [19]. Similar 
to MEK inhibition, the expression of myrAKT3 reduced 
PUMA levels in presence of cisplatin (Figure 3C). To 
further examine the role of PUMA in cisplatin-induced 
apoptosis, we performed siRNA-mediated knockdown of 
BBC3. The knockdown diminished the cisplatin dependent 
induction of BBC3 mRNA and PUMA protein levels to 
a similar extent as the MEK inhibitor (compare Figure 
3D and 3B). In both tested cell lines, PUMA depletion 
reduced the levels of cleaved caspase 3 without affecting 
DNA damage, as judged by unchanged levels of the DNA 
damage indicator P-p53 (Ser15) (Figure 3E). 
Figure 5: Downregulation of functional SPRY2 contributes to apoptosis resistance in a PUMA-independent manner 
A: Real-time PCRs displaying the expression of SPRY1-4 mRNAs in A375 and LOX IMVI cells after MEK inhibition. Cells were treated 
with PD (2 µM) or DMSO for 24h. Relative levels of SPRY1-4 mRNAs were normalized to RS14 levels and DMSO-treated cells were set 
as reference. Error bars: SD of three independent experiments. n.e.: not expressed. B: Western blot displaying SPRY2 and SPRY4 levels in 
response to MEK inhibition as described in A. Tubulin served as loading control. C, upper image: Western blot showing the expression of 
myc-tagged SPRY2DN and SPRY4DN in A375 cells. β-actin served as loading control. C, lower image: A375 cells expressing SPRY2DN, 
SPRY4DN or empty control vector were seeded at equal density and were treated with cisplatin. The number of living cells was determined 
48h after treatment. Data are presented as % of seeded cells and are derived from two experiments each performed in triplicates. D: 
Western blot displaying P-AKT (Ser473) and P-ERK1/2 (Thr202/Tyr204) levels in A375 control, SPRY2DN or SPRY4DN expressing 
cells. Vinculin served as loading control E: BBC3 (PUMA) mRNA levels in A375 control, SPRY2DN or SPRY4DN expressing cells in 
absence or presence of cisplatin (10 µM, 24h). Data are derived from two independent experiments, each done in triplicates.
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Receptor tyrosine kinases mediate MEK inhibitor-
induced AKT activation 
Receptor tyrosine kinases (RTK) are efficient 
inducers of RAS, CRAF and AKT, which are all induced 
in response to the observed MEK inhibition. RTKs 
have been implicated in drug resistance in melanoma 
and are involved in mediating the increased invasion 
phenotype which is seen in some melanoma cells after 
MEK inhibition [20]. Thus, we tested whether they 
are also involved in our apoptosis-regulating crosstalk 
mechanism. We first checked whether the ERK1/2-PI3K 
crosstalk occurs under conditions in which ERK1/2 can be 
specifically activated by receptor tyrosine kinase signaling. 
To accomplish this, we used a murine melanocyte cell line 
which is transgenic for an engineered chimeric EGFR 
construct (Figure S5A). When these cells are starved by 
cultivation under reduced serum conditions, they become 
quiescent, but can be specifically stimulated by EGFR 
activation, resulting in proliferation and migration [21-
23]. EGF treatment led to strong activation of ERK1/2 
and AKT in the melanocytes (Figure S5A). In presence 
of MEK inhibitor, AKT signaling was enhanced and was 
maintained for a much longer timespan compared to the 
controls. These data indicate that RTK signaling can 
mediate the ERK1/2-PI3K crosstalk, implying a possible 
involvement of RTKs in PD-mediated AKT activation 
in the melanoma cell lines. A comparable experiment 
was therefore conducted with the human melanoma cell 
lines A375 and LOX IMVI. As these cells express many 
different RTKs which could potentially be involved, they 
were first starved and then treated with 10% FCS. FCS 
contains numerous growth factors [24], and by using FCS 
we intended to reach simultaneous activation of several 
different receptors (Figure S5B). Under starved conditions, 
phosphorylated AKT was almost invisible in both cell 
lines. In contrast, there was a robust P-ERK1/2 signal, 
which is attributed to the activating BRAFV600E mutation. 
FCS stimulation led to enhanced AKT in both cell lines, 
Figure 6: Downregulation of SPRED1/2 mimicks the effect of MEK inhibitor on PUMA and apoptosis resistance A: 
Real-time PCRs displaying the expression of SPRED1-2 mRNAs in A375 and LOX IMVI cells after MEK inhibition. Cells were treated 
with PD (2 µM) or DMSO for 24h. Relative levels of SPRED mRNAs were normalized to RS14 levels and DMSO-treated cells were set as 
reference. Error bars: SD of two independent experiments, each done in triplicate. B: Western blot displaying SPRED1 and SPRED2 levels 
in response to MEK inhibition as described in A. Tubulin served as loading control. C: A375 cells were transfected with control siRNA or 
siRNAs directed against SPRED1 and SPRED2. After 24h, cells were treated with 10 µM cisplatin for 48h, and cells were counted. Data 
are presented as % of seeded cells and are derived from two experiments each performed in triplicates. D: A375 cells were transfected 
with control siRNA or siRNAs directed against SPRED1 and SPRED2. Active RAS was precipitated from whole cell lysates, and RAS 
levels were determined. Lysates treated with GDP or GTP served as negative and positive control, respectively. Input lysates were blotted 
and analyzed for presence of P-AKT (Ser473), P-ERK1/2 (Thr202/Tyr204), SPRED1, SPRED2, and vinculin as loading control. E: BBC3 
(PUMA) mRNA levels in A375 cells transfected with control (ctrl) or SPRED1/2 (S1/2) siRNA in absence or presence of cisplatin (10 µM, 
24h). Data are derived from three independent experiments, each done in triplicates.
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and, in case of A375 cells, to reduced ERK1/2 signaling 
over time. Again, MEK inhibition resulted in enhanced 
and longer lasting AKT activation in both melanoma 
cell lines. These data indicate that the MEK inhibitor 
dependent PI3K pathway activation can be mediated by 
growth stimuli which are present in FCS. In case of A375 
cells, MEK inhibition even induced AKT phosphorylation 
in absence of FCS (Figure S5B, lane 2). 
It was previously reported that transcriptional 
induction of IGF1 can occur in response to BRAF 
inhibition [9]. To check whether MEK inhibition could 
also affect expression of RTK ligands, we investigated 
the RNA levels of EGF, IGF1, PDGF and HGF in A375 
and LOX IMVI cells. HGF was detected in none of the 
two cell lines (data not shown), but EGF, IGF1 and PDGF 
were expressed under standard growth conditions. While 
MEK inhibition had no effect on any of the investigated 
ligands in LOX IMVI cells, EGF and IGF1 were 
significantly induced by PD in A375 cells (Figure S5C). 
In case of EGF, RNA levels were increased 9-fold. EGFR 
is expressed at low or moderate levels in many melanoma 
cells [25] and was also detected in A375 and LOX IMVI 
cells (Figure 4A). The inhibition of EGFR with the small 
molecule inhibitor AG1478 had different effects on the 
cell lines: A375 cells were sensitized to cisplatin, whereas 
LOX IMVI cells were protected from cisplatin-induced 
apoptosis to a similar extent as in presence of PD (Figure 
4B). However, EGFR inhibition resensitized both cell 
lines to cisplatin in presence of PD and abolished PD-
mediated AKT activation (Figure 4A, B). 
We also investigated the impact of EGFR activation 
on two cell lines which show very low (MeWo) or high 
(451Lu) levels of apoptosis induction in response to PD 
treatment (see Figure S1B, C). Both cell lines express 
low levels of EGFR, but in MeWo cells they were slightly 
higher compared to 451Lu (Figure 4C). Interestingly, EGF 
stimulation led to an increase in downstream RAF/ERK1/2 
and PI3K/AKT pathways in MeWo, but not in 451Lu cells 
(Figure 4C and, from an independent experiment, Figure 
S5D) Furthermore, EGF enhanced survival in presence 
of cisplatin and PD only in MeWo cells (Figure 4C). 
Consequently, EGF stimulation might be involved in PD-
dependent AKT activation and protection from cisplatin in 
MeWo cells (Figure 4C, D). 
MEK inhibition relieves several feedback loops 
which contribute to PI3K pathway activation and 
apoptosis resistance
The MAPK pathway is prone to tight regulation 
mechanisms which guarantee the transient nature of 
pathway activation under physiological conditions. 
Dual specific phosphatases (DUSP), SPRY and SPRED 
family proteins are induced by the RAF/MEK/ERK1/2 
pathway [22, 26]. SPRY and SPRED proteins can exert 
Figure 7: Scheme of the MEK inhibitor induced crosstalk mechanism. A: In absence of MEK inhibitor, BRAFV600E activation 
leads to the ERK1/2-dependent induction of SPRED genes, which block RAS signaling downstream of RTKs in melanoma cells. This 
results in low PI3K pathway activity. When cells are exposed to genotoxic stress, PUMA is induced and cells undergo apoptosis. B: 
Application of MEK inhibitor abolishes the expression of SPRED1 and SPRED2 and thereby relieves the negative feedback on RTK 
signaling. As a result, the PI3K pathway is activated. This prevents the induction of the apoptosis promoter PUMA in response to genotoxic 
stress and allows enhanced survival and protection from apoptosis. 
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their function downstream of RTKs and were reported 
to be involved in RAS regulation [27, 28]. Thus, we 
hypothesized that SPRY or SPRED proteins are involved 
in MEK inhibitor dependent protection from apoptosis. 
Along these lines, MEK inhibition reduced RNA and 
protein levels of SPRY2, SPRY4 (Figure 5A, B) as well 
as SPRED1 and SPRED2 (Figure 6A, B) in A375 and 
LOX IMVI cells. In addition, SPRY1 was reduced on 
RNA level in A375 cells (Figure 5A). It was previously 
demonstrated that a reduction of SPRY genes increases 
RAS downstream signaling in melanoma [29]. To 
investigate the impact of SPRY2 and -4 on protection from 
apoptosis, we overexpressed dominant negative constructs 
of both proteins in A375 cells. The mutants destroying 
Tyr55 or Tyr53 of SPRY2 and SPRY4, respectively, are 
incapable of mediating RTK feedback inhibition, but 
instead act as dominant negative protein versions [30-32]. 
SPRY2DN, but not SPRY4DN, enhanced melanoma cell 
survival in presence of cisplatin (Figure 5C). However, the 
levels of activated AKT or cisplatin-induced BBC3 were 
neither affected by SPRY2DN nor by SPRY4DN (Figure 
5D, E), suggesting that the protection from apoptosis 
by SPRY2DN occurs via an AKT/PUMA-independent 
mechanism. 
In addition, SPRED1 and -2 are established negative 
regulators of the RAS/RAF/ERK1/2 pathway. To test 
whether SPRED1 and -2 are involved in mediating the 
observed ERK1/2/AKT crosstalk, we knocked down both 
genes simultaneously. Again, we observed a protection 
from genotoxic apoptosis (Figure 6C, Figure S6). This 
went along with a modest enhancement of active RAS 
and AKT (Figure 6D) and with the prevention of cisplatin-
induced BBC3 (Figure 6E).
In summary, our data reveal a complex RTK-
associated and SPRED1/2-mediated feedback network 
which can be relieved by MEK inhibition and thereby 
protects from DNA damage induced apoptosis in 
melanoma cells (summarized in Figure 7). 
DISCUSSION
In the present study we show that inhibition 
of the MAPK pathway has the potential to protect 
melanoma cells from apoptosis induced by genotoxic 
damage. This effect was conveyed by activation of the 
PI3K pathway which occurred shortly after the start of 
MEK inhibition and was mediated by multiple factors. 
Several negative feedback components including SPRY 
and SPRED proteins were affected by MEK inhibition. 
SPRED1 is a very efficient regulator of RAS and certain 
inherited SPRED1 mutants cause the Legius syndrome 
which belongs to the so-called “rasopathies” – diseases 
characterized by enhanced RAS signaling [33]. SPRED1 
exerts its function by binding and inhibiting neurofibromin 
1 (NF1), one of the major RAS GTPase activating proteins 
[28]. NF-1 was recently identified as top hit in an shRNA 
screen designed to identify genes whose disruption 
convey BRAF inhibitor resistance in melanomas [34]. It is 
mutated in a significant number of melanomas, including 
those with BRAF inhibitor resistance [35, 36]. We could 
demonstrate that siRNA-mediated reduction of functional 
SPRED1 and 2 siRNA aids in enhancing RAS activity 
and reducing PUMA-dependent apoptosis by genotoxic 
stress. Furthermore, reduction of SPRY2 also contributed 
to protection from apoptosis, as dominant negative 
SPRY2 doubled the fraction of cells which survived 
cisplatin treatment. Interestingly, this protective effect did 
not go along with AKT induction or PUMA regulation, 
suggesting an independent additional mechanism which 
might contribute to the observed MEK inhibitor dependent 
effect. Of note, it was recently reported that a reduction 
of SPRY2 by either BRAF inhibition or siRNA enhanced 
the responsiveness to exogenous ligands and thereby 
enhanced mitogenic signaling [29], thus indicating that 
a reduction of SPRY2 can provide conditions which also 
facilitate resistance to BRAF inhibitor monotherapy. 
However, we also observed the downregulation of 
SPRY2 and 4 as well as SPRED1 and -2 in a melanoma 
cell line (451Lu) which is MEK inhibitor sensitive and 
does not display enhanced AKT activation by PD (Figure 
S7). We propose that the repression of SPRY and SPRED 
genes is a common phenomenon in MEK inhibited 
melanoma cells, but that it can only contribute to drug 
resistance and protection from genotoxic damage in 
presence of a permissive cellular context. Melanoma cells 
which express a certain set of receptor tyrosine kinases 
supposedly provide this permissive condition. Our data 
indicate that EGFR belongs to the potent RTKs which 
permit the MEK-inhibitor dependent AKT activation, 
followed by enhanced apoptosis resistance. 
In BRAFV600E mutant colorectal cancer cells, which 
generally express higher levels of EGFR than melanomas, 
activation of EGFR and downstream pathways occurs in 
response to vemurafenib and is responsible for resistance 
towards this BRAF inhibitor [37]. EGFR-expressing cells 
seem to be particularly prone to feedback activation in 
several cancer cell types, such as melanoma (our data 
and [38]), colon cancer [37] and breast cancer [39]. 
Recent studies show that EGFR expression occurs in a 
significant percentage of BRAF resistant melanomas, 
and receptor activation, though disadvantageous under 
normal conditions, becomes beneficial when the MAPK 
pathway is blocked in BRAFV600E positive melanomas 
[40]. Also, FOXD3-dependent upregulation of the EGFR 
family member ERBB3 was described after BRAF- or 
MEK inhibition in melanoma cells, resulting in enhanced 
responsiveness to ERBB3 ligands and the sensitization 
towards the BRAF inhibitor PLX4720 by lapatinib [41]. 
Therefore, it is highly likely that ERBB3 also belongs to 
the factors which determine the permissive environment. 
Apart from receptor expression, the corresponding 
set of ligands has to be expressed and shedded in order 
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to allow the protective effect of MEK inhibition towards 
genotoxic stress. We found that in MeWo cells only 
the addition of EGF caused the protective effect of PD 
towards cisplatin, indicating that these cells do not 
produce sufficient ligands to reach autocrine stimulation. 
In order to produce and secrete sufficient ligands, cells 
have to express a certain molecular equipment. For 
example, EGFR ligands can be induced by EGFR itself 
[42], by RAS [43], or IL-1β [44]. The shedding of EGFR 
ligands is mainly dependent on the metalloproteases 
ADAM-17 and ADAM10 [45], the latter being induced 
by PAX2 in melanoma [46]. Interestingly, Vultur et al. 
described recently the activation of several RTKs and the 
downstream signal transducer STAT3 in 20% of MEK-
inhibitor treated melanoma cells [20]. They showed 
that MEK inhibitor induced STAT3 activation results in 
increased melanoma cell invasion. It is well possible that 
their reported STAT3-dependent invasion and our AKT-
dependent protection from apoptosis are the consequences 
from similar upstream events.
Mechanistically, we found that AKT-dependent 
reduction of the pro-apoptotic effector PUMA was 
involved in the protection from apoptosis. PUMA is a 
FOXO1/3a target which is strongly induced in presence 
of genotoxic stress [47], [48] and is implicated in the 
induction of apoptosis in melanoma [49]. Importantly, 
PUMA expression correlates inversely with the melanoma 
malignancy grade, and weak PUMA expression is 
associated with poorer overall survival [19]. By reducing 
PUMA levels, MEK-inhibition can therefore evoke 
unexpected pro-tumorigenic effects, even in BRAFV600E-
mutant melanomas. It is however possible that apart from 
PUMA, other AKT downstream targets also contribute to 
the observed anti-apoptotic effect.
Compensatory PI3K pathway activation might be 
a serious problem in the clinical setting, where BRAF- 
and MEK inhibitors can encounter intrinsic [50-52] as 
well as acquired [5, 9] PI3K pathway reactivation which 
is likely involved in tumor relapse. After the tumors 
reappear, chemotherapeutic and DNA damaging agents 
are often applied, usually without benefit for the patient. 
The reason for this might be found, at least partially, in 
the apoptosis resistance conferred by PI3K pathway 
activation. Consequently, PI3K pathway inhibitor 
combination therapies are a promising approach. There are 
encouraging preclinical data addressing this strategy. In 
melanoma cell lines, acquired BRAF inhibitor resistance 
is overcome by simultaneous MEK and PI3K/mTOR 
inhibition [53]. Along these lines, combined MEK and 
PI3K/mTORC inhibition also leads to tumor regression in 
murine melanoma models driven by mutant RAS [54]. In 
cancer patients, dual inhibition of BRAF/MEK/ERK1/2 
and PI3K/AKT/mTOR pathways is in phase I clinical 
trials [55]. So far, only few melanoma patients were 
enrolled in this study, and it is too early to state whether 
the dual inhibition strategy is more successful than BRAF 
inhibitor monotherapy. 
In summary, our data demonstrate that MEK 
inhibition of BRAFV600E-positive melanoma cells can lead 
to AKT-dependent enhanced apoptosis resistance towards 
genotoxic stress, implying a careful choice of pathway 
inhibitors in combination therapies.
METHODS
Compounds
The MEK inhibitor PD184352 (in short PD) and 
GDC-0941 were purchased from Axon Medchem and 
Selleckchem, respectively. The PI3K inhibitor LY294002, 
the EGFR inhibitor AG1478 and cisplatin were obtained 
from Calbiochem. ON-TARGET plus SMART pool 
siRNA for BBC3 (PUMA), SPRED1, SPRED2 and 
non-targeting siRNA were from Thermo Scientific. For 
transfection of siRNA, X-tremeGENE siRNA Transfection 
Reagent (Roche) was used according to the manufacturer`s 
instructions.
Cell lines and plasmids
A375, Mel Ho, and SK MEL28 were purchased from 
ATCC. LOX IMVI, RPMI 7951, UACC-62, M19MEL, SK 
MEL2, SK MEL5 are part of the NCI-60 panel and were 
obtained from the NCI/NIH (DCTD Tumor Repository, 
National Cancer Institute at Frederick, Frederick, 
Maryland). 451Lu and MeWo cells were kindly provided 
by Meenhard Herlyn (Wistar Institute, Philadelphia, PA) 
and Anja Bosserhoff, (Institute of Pathology, University 
of Regensburg, Germany), respectively. All cell lines were 
maintained in DMEM with 10% FCS at 37° and 5% CO2. 
HERmrk cells were cultivated as described earlier [56]. 
Cell lines were authenticated using the PowerPlex 16 
DNA typing system (Promega). 
The plasmid containing the constitutively active 
myristoylated AKT3 (pBabe-puroL-Myr-HA-Akt3) 
was purchased from Addgene (Addgene plasmid 9019). 
Dominant negative constructs of SPRY2 and SPRY4 
(pcDNA3 SPRY2DN, pcDNA3 SPRY4DN) [32] were 
kindly supplied by Akihiko Yoshimura (original names: 
pcDNA3 SPRY2 Y53A and pcDNA SPRY4 Y55A) 
(Kurume, Japan). Truncated dominant negative versions of 
SPRED1 and SPRED2 (SPRED1DN, SPRED2DN) were 
designed as described earlier [57] and cloned in p201iEP 
for lentiviral delivery.
Protein extraction and Western blot 
Cells were lysed in lysis buffer (20 mM HEPES 
(pH 7.8), 500 mM NaCl, 5 mM MgCl2, 5 mM KCl, 
Oncotarget5050www.impactjournals.com/oncotarget
0.1% deoxycholate, 0.5% Nonidet-P40, 10 mg/ml 
aprotinin, 10 mg/ml leupeptin, 200 mM Na3VO4, 1 mM 
phenylmethanesulphonylfluoride and 100 mM NaF). 30-
50 µg of protein lysate was separated by SDS-PAGE and 
transferred to nitrocellulose membranes. Anti-β-actin (C4) 
antibody was purchased from Santa Cruz Biotechnology 
(sc-47778). Antibodies directed against P-ERK1/2 
(Thr202/Tyr204), P-AKT (Ser473), P-FOXO1/3a 
(Thr24/32), P-MEK1/2 (Ser217/221) cleaved caspase 3 
(Asp175), P-CRAF (Ser259), PUMA, myc-tag, and P-p53 
(Ser15) were purchased from Cell Signaling Technologies. 
Antibodies against SPRY2 and SPRY4 were purchased 
from Sigma Aldrich, the SPRED1 antibody was acquired 
from Thermo Scientific. The antibody against SPRED2 
was kindly provided by Kai Schuh (Würzburg, Germany). 
Generally, the presented protein blots are representative 
for 2-3 independent experiments.
RAS activity assay 
750 µg of total protein lysate was used to determine 
the levels of active, GTP-bound RAS using the Active 
RAS Pull-Down and Detection Kit (Thermo Scientific), 
according to the manufacturer’s instructions.
RNA isolation and real-time PCR
RNA isolation was performed with peqGOLD 
TrifastTM solution (PEQlab). Whole RNA (1-4 µg) was 
reversely transcribed using the RevertAidTM First Strand 
cDNA Synthesis Kit (Fermentas). Quantitative real-time 
PCR was performed using a Mastercycler ep realplexTM 
(Eppendorf). Gene expression was normalized to RS14. 
Cell cycle analysis
Cells were harvested and fixed in 70% ETOH at 
-20°C for at least 24 hours and rinsed twice with PBS. For 
flow cytometry analysis, cells were treated with 0.5 mg/ml 
RNase A for 30 min at 37°C before the DNA was stained 
with 69 mM propidium iodide in 38 mM sodium citrate. 
Flow cytometry was performed using a Cytomics FC 500 
flow cytometer (Beckman Coulter). Results were analyzed 
using the cxp analysis software (Beckman Coulter).
Proliferation assay
0.5-1.0 x105 melanoma cells were seeded in 
triplicates on six-well dishes. 24 hours after seeding cells 
were treated with inhibitors and cisplatin as indicated. 
Media containing the drugs was changed every other day. 
At indicated time points, all cells were harvested and the 
number of living cells was determined using a Neubauer 
hemocytometer at indicated time points, using the trypane 
blue exclusion method.
Statistical analyses
Data presented in the bar graphs represent the mean 
values of at least three independent data points as indicated 
in the respective figure legends. The error bars represent 
the standard deviation. Significance was determined using 
an unpaired two-tailed t-test (*: p≤0.05; **: p≤0.01; ***: 
p≤0.001).
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